Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ocugen Inc 11 GREAT VALLEY PARKWAY MALVERN PA 19355 USA

ocugen.com P: 484-328-4701

Description:

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania.

Key Statistics

Overview:

Market Capitalization, $K 404,005
Enterprise Value, $K 367,345
Shares Outstanding, K 257,328
Annual Sales, $ 6,040 K
Annual Net Income, $ -63,080 K
Last Quarter Sales, $ 6,040 K
Last Quarter Net Income, $ -9,490 K
EBIT, $ -71,560 K
EBITDA, $ -71,040 K
60-Month Beta 3.49
% of Insider Shareholders 3.48%
% of Institutional Shareholders 10.27%
Float, K 248,373
% Float 96.52%
Short Volume Ratio 0.58

Growth:

1-Year Return 139.62%
3-Year Return -82.06%
5-Year Return -84.97%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 99.45%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.04 on 04/16/24
Latest Earnings Date 05/14/24 [BMO]
Earnings Per Share ttm -0.27
EPS Growth vs. Prev Qtr 33.33%
EPS Growth vs. Prev Year 60.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-60 on 09/30/19

OCGN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -102.97%
Return-on-Assets % -77.75%
Profit Margin % -1,044.37%
Debt/Equity 0.07
Price/Sales 69.49
Price/Cash Flow N/A
Price/Book 8.41
Book Value/Share 0.16
Interest Coverage -0.97
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar